TickerTalks
Browse all tickers →
TickerTalks›$CAI
CACAI

Caris Life Sciences, Inc.

Hot onWhy it's trendingX mentions rising faster than the marketMoving on elevated volumeBacked by solid revenue growth
$CAI·$8.5B·Biotechnology·Healthcare
$29.98-3.0%YTD+10.6%1Y-10.3%
Price updated 13h ago·X counts updated 5d ago
CACAI
$CAICaris Life Sciences, Inc.
$29.98-3.04%73 posts1.4×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CAI on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

73X posts · last 7 days
Sep 1Sep 14
Chatter Meter
1.4×
QuietNormal · 1×Loud

How loud $CAI's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 90% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-08-28

Caris Life Sciences chatter is thin but positive. Traders cite the Krypton Research team +51% closed and +40% ongoing thesis (diagnostics too cheap and biggest AI beneficiaries), inclusion in Accelerating Earnings and Biotechnology bullish-scan screens, and diagnostics 'playing out' with CAI/WGS/XGN. A cautionary note that BTC beat most of these over 5 years. Overall bullish.

Read what X is saying about $CAI

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CAI — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-18

The move is getting stronger, with heavier trading behind it.

Caris Life Sciences up ~9% on molecular-diagnostics growth — insider selling ~$17M on Sept 4/17 warrants attention.

Caris Life Sciences is a recently public molecular-profiling and cancer-diagnostics operator — the story is an AI-driven diagnostics platform that has been executing on real revenue growth since IPO.

  • The operating side is running: Q1 revenue grew 79% YoY (Q4 was up 193% off soft base), TTM gross margin is 69%, TTM operating margin is 16%, and last two EPS prints beat consensus modestly — analysts model FY26 EPS at $0.03 with continued growth into FY27.
  • The strategic marketing pipeline is dated: the Sept 8 Kevin Costner national commercial to raise awareness of early cancer detection is a real brand-building step, plus the Sept 17 Seeking Alpha 'diagnostics growth with room to run' framing captures the compounder thesis.
  • The insider tape is a big caution: officer Brian Brille sold ~$12.1M plus $1.95M M-Exempt on Sept 17, officer Spetzler sold ~$2.95M plus $1.22M M-Exempt on Sept 4 — a real ~$17M insider cluster into the tape's strength, and the 82nd-percentile of 52-week range plus 45% above the 50-day says this is a hot momentum name.

Nov 4 earnings extends the run if Q3 EPS beats $0.03 consensus with continued diagnostics-volume growth and any specific insurance-coverage-expansion commentary. What actually invalidates is either a specific molecular-diagnostics competitive readout (Foundation Medicine, Guardant Health), a fresh insurance-coverage decision that tightens reimbursement, or another Brille/Spetzler-scale insider cluster — the fundamentals support the reversal.

Agrees with X sentimentThe X thin bullish read on the Krypton Research thesis, +51% closed and +40% ongoing, is fair — the fundamentals do back the diagnostics-growth framing; the ~$17M insider cluster is the counter-signal the crowd needs to weight.

What to watch: Q3 earnings Nov 4 — diagnostics volume growth, insurance-coverage expansion, and margin trajectory; competitive readout from Foundation/Guardant, insurance-coverage tightening, or further insider cluster invalidates.

On the calendar: 2026-11-04 — Q3 earnings

large insider selling clusterrecent ipo

Read the AI verdict on $CAI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Precision oncology TechBio company using AI on comprehensive molecular tumor profiles to guide cancer treatment decisions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CAI.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $CAI

Partial — AI-driven comprehensive molecular tumor profiling (Caris Molecular Intelligence) benefits from the precision-oncology re-rating; as a TechBio service company it captures oncology R&D tailwind rather than direct product upside from mRNA/GLP-1 catalysts.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
14.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
6.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.00$0.01-139.2%
Q1 2026May 7, 2026$-0.00$-0.02+91.0%
Q4 2025Feb 26, 2026$0.28$0.01+2700.0%
Q3 2025Nov 5, 2025$0.08$-0.08+200.0%
Next earningsWed, Nov 4·consensus EPS $0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$216.2M+78.8%65.4%2.4%$-0.00$22.5M
Q4 FY25$292.9M+192.7%75.4%30.2%$0.29$39.7M
Q3 FY25$216.8M+168.8%68.0%15.1%$0.09$55.3M
Q2 FY25$181.4M+79.9%62.7%9.9%$-1.93$5.9M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.0B$1.0B – $1.0B$0.12$0.11 – $0.1310
FY27$1.2B$1.2B – $1.2B$0.35$0.27 – $0.4310
FY28$1.4B$1.4B – $1.5B$0.54$0.21 – $0.7711
FY29$1.6B$1.6B – $1.7B$0.77$0.74 – $0.795
FY30$1.8B$1.8B – $1.9B$0.93$0.89 – $0.955

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.78%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+39.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+42.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 11.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today130.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.685-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 17Brian J BrilleSee Remarks400.0K sh$12.1MSellSep 4Spetzler David BaxleyPresident119.2K sh$3.0MSellSep 3Spetzler David BaxleyPresident478.0K sh$11.9MBuyMay 15Jon HalbertDirector68.0K sh$990KBuyMay 11Jeff L VacircaDirector31.1K sh$501K
+ 18 other (10 awards · 5 inkinds · 3 exempts) in window

See when $CAI insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 148-K — Item 7.01: Press release / Reg FD
AI summary

Caris Life Sciences (CAI) filed a Reg FD (Item 7.01) disclosure on September 14, 2026, announcing that company representatives will present an investor presentation at the Morgan Stanley 24th Annual Global Healthcare Conference beginning that date, and at other investor conferences and meetings going forward. The presentation is available on the company's IR website. No new financial disclosures or corporate actions are included in the filing text. This is a routine conference presentation disclosure.

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
AI summary

Caris Life Sciences, Inc. (CAI) held its 2026 Annual Meeting of Shareholders on June 4, 2026, with 273,714,520 of 282,662,545 eligible shares represented (96.8% quorum). Shareholders voted on two proposals: (1) election of ten director nominees to serve until the 2027 Annual Meeting, and (2) ratification of Deloitte & Touche LLP as auditor for fiscal year 2026. All ten directors were elected, though Peter Castleman drew notably higher withhold votes (~62M) compared to peers (~34–48M); Deloitte ratification vote totals were cut off in the excerpt but both proposals passed. This is a routine annual governance filing with no strategic or financial significance.

8-KAgreement terminatedApr 28-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
+ 14 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Caris Life Sciences: Diagnostics Growth With Room To Runseekingalpha.com·2d agoCaris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?zacks.com·3d agoCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detectprnewswire.com·11d agoCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancerprnewswire.com·17d agoCaris Life Sciences study finds AI tool could guide pancreatic cancer treatment choiceproactiveinvestors.co.uk·23d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $CAI on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport